Search

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)

CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.

Read more

EHA donates €250,000 to Médecins Sans Frontières

The EHA Board is actively implementing support actions to hematologists and hematology patients in Ukraine and to those who are forced to leave the country.

Read more

EHA and Polish Society’s third tutorial together focused on myeloid and lymphoid leukemias

Seventy-five participants from Europe and the Middle East learned about the advances in biology, genetic characteristics, diagnostic approaches and therapy of leukemias during the EHA-PTHiT Hematology Tutorial on Myeloid and Lymphoid Leukemias in Warsaw, Poland.

Read more

Scientific Program Committee, EHA Congress 2024

Current committee members
Brian Huntly, United Kingdom (Chair)
Martin Dreyling, Germany (Chair elect)
Konstanze Döhner, Germany (Past Chair)
Marta Morado, Spain (Local representative)
Gabriela Baerlocher, Switzerland
Tom Cupedo, The Netherlands
Florence Cymbalista, France
Mariane De Montalembert, France
Jordi Esteve, Spain
Thoas Fioretos, Sweden
Sara Ghorashian, United Kingdom
Domenico Girelli, Italy
Mats Jerkeman, Sweden
Ulrich…

Read more

Research Committee

Current committee members
Brian Huntly, United Kingdom (Chair)
Ruud Delwel, The Netherlands (Vice-Chair)
Dominique Bonnet, United Kingdom (EHA Board representative)
Shai Izraeli, Israel (TRTH representative)
David Kent, United Kingdom (Fellowships and Grants representative)
Alba Maiques Diaz, Spain (YoungEHA representative)
Martina Muckenthaler, Germany (HemaSphere representative)
Andreas Trumpp, Germany (Supernumerary…

Read more